Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

UCB Looks To Its Next Wave Of Innovative Products

Executive Summary

Early clinical-stage products for neurological and autoimmune diseases are progressing through the European biopharma's pipeline.

You may also be interested in...



UCB Buoyed By More Positive Bimekizumab Data

The Belgian group has a lot of catching up to do with Cosentyx and Taltz already well established but is confident bimekizumab’s mechanism of action, which neutralizes both IL-17A and IL-17F cytokines, offers an advantage over those two blockbusters.

UCB's Head of Corporate Strategy On Deals, Divestments And Sector-Wide Challenges

UCB's recently appointed head of corporate strategy and business development Alexander Moscho, who joined the company in October 2017, talks to Scrip about UCB's future growth, internal R&D pipeline and potential for significant deal-making in 2018.

Peptomyc Battles Cancer R&D Conventions

Laura Soucek, one of In Vivo’s 2020 Rising Leaders, is hoping to take Barcelona-based start-up Peptomyc to the next level. The company is nearing the clinic with an inhibitor of the transcription factor Myc, which is involved in the regulation of cellular proliferation, but can also be a driver of cancer.

Topics

Related Companies

UsernamePublicRestriction

Register

LL1122620

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel